Bristol-Myers Squibb has turned to A-Alpha Bio to discover “molecular glue,” a substance responsible for enabling drug molecules to attach to the proteins responsible for diseases. Many such proteins propagate diseases but cannot be treated by drugs, as they lack the ability to stick or interact together. A-Alpha Bio intends to employ its machine-learning technology to analyse protein-protein binding so that a solution can be discovered. The concept of molecular glues is gaining traction in the drug R&D area known as protein degradation.
Read More from MedCityNews
